Advertisement

Determination of the Immunoreactivity of Radiolabeled Monoclonal Antibodies

  • Gail Rowlinson-Busza
Part of the Methods in Molecular Medicine book series (MIMM, volume 40)

Abstract

Radiolabeled monoclonal antibodies (mAbs) are in use for numerous immunoassays and localization studies both in vitro and in vivo. It is often important to determine to what extent the radiolabeling procedure has affected the immunoreactivity of the antibody. If, for example, the radioisotope was inserted in the antigen-binding site, this would adversely affect the ability of the antibody to bind to its antigen. It is possible that, by changing the labeling technique or the radioisotope, this loss of immunoreactivity could be minimized. For example, if the antigen-binding site contains tyrosine, then the usual oxidation methods of labeling with radioiodine (1,2) may iodinate this important tyrosine residue. Other labeling methods may be more appropriate for these antibodies. For example, Bolton-Hunter reagent (3) can be used to iodinate antibodies on a lysine residue. Most chelating agents used for radiolabeling with metals are linked to the protein via a lysine residue, so if there is lysine in the antigen-binding site of the antibody, radiometals may not be the most appropriate isotope to use. However, the antibody is likely to contain a number of tyrosine and lysine residues that can be labeled, so the reduction in immunoreactivity caused by radiolabeling may not be too great. The magnitude of the effect will depend on the particular antibody.

Keywords

Lysine Residue Antibody Concentration Tissue Culture Medium Microfuge Tube Dibutyl Phthalate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Fraker, P. J. and Speck, J. C., Jr. (1978) Protein and cell membrane iodinations with a sparingly soluble chloramide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril. Biochem. Biophys. Res. Commun. 80, 849–857.CrossRefPubMedGoogle Scholar
  2. 2.
    Markwell, M. A. K. (1982) A new solid-state reagent to iodinate proteins. Anal. Biochem. 125, 427–432.CrossRefPubMedGoogle Scholar
  3. 3.
    Bolton, A. E. and Hunter, W. M. (1973) The labeling of proteins to high specific radioactivities by conjugation to a 125I-containing acylating agent. Biochem. J. 133, 529–539.PubMedGoogle Scholar
  4. 4.
    Lindmo, T., Boven, E., Cuttitta, F., Fedorko, J., and Bunn, P. A., Jr. (1984) Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J. Immunol. Methods 72, 77–89.CrossRefPubMedGoogle Scholar
  5. 5.
    Segal, D. M. and Hurwitz, E. (1977) Binding of affinity cross-linked oligomers of IgG to cells bearing Fc receptors. J. Immunol. 118, 1338–1347.PubMedGoogle Scholar
  6. 6.
    Scatchard, G. (1949) The attractions of proteins for small molecules and ions. Ann. NYAcad. Sci. 51, 660–672.CrossRefGoogle Scholar
  7. 7.
    Arklie, J. (1981) Studies of human epithelial cell surface using monoclonal antibodies. D.Phil. Thesis, Oxford University.Google Scholar
  8. 8.
    Drewinko, B., Romsdahl, M. M., Yang, L. Y., Ahearn, M. J., and Trujillo, J. M. (1976) Establishment of a human carcinoembryonic antigen-producing colon adenocarcinoma cell line. Cancer Res. 36, 467–475.PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2000

Authors and Affiliations

  • Gail Rowlinson-Busza
    • 1
  1. 1.Antisoma Research LaboratoriesSt. George’s Hospital Medical SchoolLondonUK

Personalised recommendations